International Journal of Biomedicine. 2022;12(4):526-529.
DOI: 10.21103/Article12(4)_RA5
Originally published December 5, 2022
The new coronavirus (SARS-COV2), which causes coronavirus illness, has expanded globally, impacting millions of individuals. In comparison to female patients, males have a higher prevalence, morbidity, and death rate from this condition, according to international statistics. Androgens have been implicated in the pathophysiology of COVID-19. This review's objective is to explain the potential connection between the pathophysiology of androgen and the infectivity mechanism of the coronavirus as well as the association between SARS-COV2 and hair disorders. This might assist in clarifying androgen's involvement in COVID-19 prognosis and therapy.
1. World Health Organization; 2020. Coronavirus disease (COVID-19): situation report, 51. Geneva: Available from: https://apps.who.int/iris/handle/10665/331475.
2. Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, Rovida F, Baldanti F, Marseglia GL. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr. 2020 Sep 1;174(9):882-889. doi: 10.1001/jamapediatrics.2020.1467.
3. Jian L, Yi W, Zhang N, Wen W, Krysko O, Song WJ, Bachert C. Perspective: COVID-19, implications of nasal diseases and consequences for their management. J Allergy Clin Immunol. 2020 Jul;146(1):67-69. doi: 10.1016/j.jaci.2020.04.030.
4. Bennani NN, Bennani-Baiti IM. Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy. Ann Oncol. 2020 Nov;31(11):1585-1586. doi: 10.1016/j.annonc.2020.08.2095.
5. Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev. 2006 Dec;58(4):782-97. doi: 10.1124/pr.58.4.9.
6. Rastrelli G, Di Stasi V, Inglese F, Beccaria M, Garuti M, Di Costanzo D, Spreafico F, Greco GF, Cervi G, Pecoriello A, Magini A, Todisco T, Cipriani S, Maseroli E, Corona G, Salonia A, Lenzi A, Maggi M, De Donno G, Vignozzi L. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology. 2021 Jan;9(1):88-98. doi: 10.1111/andr.12821.
7. Bobjer J, Katrinaki M, Tsatsanis C, Lundberg Giwercman Y, Giwercman A. Negative association between testosterone concentration and inflammatory markers in young men: a nested cross-sectional study. PLoS One. 2013 Apr 18;8(4):e61466. doi: 10.1371/journal.pone.0061466.
8. Maggio M, Basaria S, Ceda GP, Ble A, Ling SM, Bandinelli S, Valenti G, Ferrucci L. The relationship between testosterone and molecular markers of inflammation in older men. J Endocrinol Invest. 2005;28(11 Suppl Proceedings):116-9.
9. Zitzmann M. The role of the CAG repeat androgen receptor polymorphism in andrology. Front Horm Res. 2009;37:52-61. doi: 10.1159/000175843.
10. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3320-3. doi: 10.1073/pnas.94.7.3320. Erratum in: Proc Natl Acad Sci U S A 1997 Jul 22;94(15):8272.
11. Wambier CG, Goren A, Vaño-Galván S, Ramos PM, Ossimetha A, Nau G, Herrera S, McCoy J. Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res. 2020 Nov;81(7):771-776. doi: 10.1002/ddr.21688.
12. McCoy J, Wambier CG, Vano-Galvan S, Shapiro J, Sinclair R, Ramos PM, Washenik K, Andrade M, Herrera S, Goren A. Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? J Cosmet Dermatol. 2020 Jul;19(7):1542-1543. doi: 10.1111/jocd.13455.
13. Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, Carbone GM, Cavalli A, Pagano F, Ragazzi E, Prayer-Galetti T, Alimonti A. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol. 2020 Aug;31(8):1040-1045. doi: 10.1016/j.annonc.2020.04.479.
14. Goren A, Vaño-Galván S, Wambier CG, McCoy J, Gomez-Zubiaur A, Moreno-Arrones OM, Shapiro J, Sinclair RD, Gold MH, Kovacevic M, Mesinkovska NA, Goldust M, Washenik K. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020 Jul;19(7):1545-1547. doi: 10.1111/jocd.13443.
15. ElFaramawy AAA, Hanna IS, Darweesh RM, Ismail AS, Kandil HI. The degree of hair graying as an independent risk marker for coronary artery disease, a CT coronary angiography study. Egypt Heart J. 2018 Mar;70(1):15-19. doi: 10.1016/j.ehj.2017.07.001.
16. Trieu N, Eslick GD. Alopecia and its association with coronary heart disease and cardiovascular risk factors: a meta-analysis. Int J Cardiol. 2014 Oct 20;176(3):687-95. doi: 10.1016/j.ijcard.2014.07.079.
17. Zhang B, Ma S, Rachmin I, He M, Baral P, Choi S, Gonçalves WA, Shwartz Y, Fast EM, Su Y, Zon LI, Regev A, Buenrostro JD, Cunha TM, Chiu IM, Fisher DE, Hsu YC. Hyperactivation of sympathetic nerves drives depletion of melanocyte stem cells. Nature. 2020 Jan;577(7792):676-681. doi: 10.1038/s41586-020-1935-3.
18. Shanshal M. COVID-19 related anagen effluvium. J Dermatolog Treat. 2022 Mar;33(2):1114-1115. doi: 10.1080/09546634.2020.1792400.
19. Domínguez-Santás M, Haya-Martínez L, Fernández-Nieto D, Jiménez-Cauhé J, Suárez-Valle A, Díaz-Guimaraens B. Acute telogen effluvium associated with SARS-CoV-2 infection. Aust J Gen Pract. 2020 Aug 26;49. doi: 10.31128/AJGP-COVID-32.
20. Grifoni E, Valoriani A, Cei F, Lamanna R, Gelli AMG, Ciambotti B, Vannucchi V, Moroni F, Pelagatti L, Tarquini R, Landini G, Vanni S, Masotti L. Interleukin-6 as prognosticator in patients with COVID-19. J Infect. 2020 Sep;81(3):452-482. doi: 10.1016/j.jinf.2020.06.008.
21. Kwack MH, Ahn JS, Kim MK, Kim JC, Sung YK. Dihydrotestosterone-inducible IL-6 inhibits elongation of human hair shafts by suppressing matrix cell proliferation and promotes regression of hair follicles in mice. J Invest Dermatol. 2012 Jan;132(1):43-9. doi: 10.1038/jid.2011.274.
22. Mauvais-Jarvis F, Klein SL, Levin ER. Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes. Endocrinology. 2020 Sep 1;161(9):bqaa127. doi: 10.1210/endocr/bqaa127.
23. Al-Kuraishy HM, Al-Gareeb AI, Faidah H, Al-Maiahy TJ, Cruz-Martins N, Batiha GE. The Looming Effects of Estrogen in Covid-19: A Rocky Rollout. Front Nutr. 2021 Mar 18;8:649128. doi: 10.3389/fnut.2021.649128.
24. Lovre D, Bateman K, Sherman M, Fonseca VA, Lefante J, Mauvais-Jarvis F. Acute estradiol and progesterone therapy in hospitalised adults to reduce COVID-19 severity: a randomised control trial. BMJ Open. 2021 Nov 30;11(11):e053684. doi: 10.1136/bmjopen-2021-053684.
25. Grymowicz M, Rudnicka E, Podfigurna A, Napierala P, Smolarczyk R, Smolarczyk K, Meczekalski B. Hormonal Effects on Hair Follicles. Int J Mol Sci. 2020 Jul 28;21(15):5342. doi: 10.3390/ijms21155342.
26. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436.
27. Mohamed MS, Moulin TC, Schiöth HB. Sex differences in COVID-19: the role of androgens in disease severity and progression. Endocrine. 2021 Jan;71(1):3-8. doi: 10.1007/s12020-020-02536-6.
28. Ghazizadeh Z, Majd H, Richter M, Samuel R, Zekavat SM, Asgharian H, Farahvashi S, Kalantari A, Ramirez J, Zhao H, Natarajan P, Goodarzi H, Fattahi F. Androgen Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men. bioRxiv [Preprint]. 2020 May 15:2020.05.12.091082. doi: 10.1101/2020.05.12.091082.
Download Article
Received October 16, 2022.
Accepted November 23, 2022.
©2022 International Medical Research and Development Corporation.
